Cross-Over Technologies

IMAT applications constituted approximately 78 percent of all technology development applications reviewed by the NCI in FY 2005, approximately 61 percent of those reviewed in FY 2006, and 72 percent of those reviewed in FY 2007 (figure 3 below). Based on this report, 415 technology-related R21, R33, and R0l grant applications were reviewed under 5 RFAs in FY 2006, representing a growth rate of 111 percent relative to FY 2002. The explosive growth rate of such applications highlights both the success of the NCI in soliciting innovative technology development proposals and the increasing importance that innovation plays in the cancer research arena. IMAT applications constituted approximately 78 percent of all technology development applications reviewed by the NCI in FY 2005 and approximately 61 percent of those reviewed in 2006. Such data indicate the strength of the IMAT Program's contribution to the NCI's technology development portfolio. Between FY 2005 and FY 2006, the IMAT Program awarded 95 research project grants, 26 of which represented new or first-time awardees. In addition, the program has made 51 awards in FY 2007, 5 to new or first-time awardees.

Technology Applications Reviewed by the National Cancer Institute.

Technology Initiatives Applications Reviewed FY 2004 - 2008

 

IMAT Contributions to the NCI's Technology Development Portfolio as a Function of All Technology Applications Reviewed by the National Cancer Institute

Examples of IMAT Investigators Utilizing IMAT-Developed Technologies In Selected NCI Programs